FDA
-
-
-
-
-
-
-
SAGE Therapeutics (SAGE) Announces Board Changes
-
-
-
-
-
-
-
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
-
-
-
-
-
-
-
Sage tumbles to record low on clinical depression pill setback
-
-
-
-
-
-
-
SAGE Therapeutics (SAGE) Reports Q1, Provides Pipeline and Business Progress
-
-
-
-
-
-
-
Sage Therapeutics (SAGE) PT Raised to $60 at Stifel
-
-
-
-
-
-
-
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
-
-
-
-
-
-
-
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
-
251,609 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All